GSK's momelotinib wins FDA and EMA orphan status for VEXAS syndrome, backed by early evidence. The company advances a phase ...
GEn1E Lifesciences Inc., a Phase 2 clinical-stage biotechnology company advancing AI-driven precision medicines for ...
While rare disease research has advanced significantly, related expertise and data are scattered across too many disconnected places.
In a rare move, nonprofit organization Blood Cancer United is buying the remaining supplies of a discontinued investigational ...
The US Food and Drug Administration (FDA) is more likely to approve drugs with an orphan designation that were indicated for ...
Detailed price information for Pasithea Therapeutics Corp (KTTA-Q) from The Globe and Mail including charting and trades.
Optum is seeing an increase of new orphan drugs, and expects this trend to continue, if not accelerate, according to a drug pipeline report from the UnitedHealth Group subsidiary. What makes this ...
FDA grants Orphan Drug Designation (ODD) to Tris Pharma’s TRN-257 for the treatment of idiopathic hypersomnia, based on the plausible hypothesis ...
Rising number, cost of drugs for rare disease therapies create new pressure on health plans, researchers report in the October issue of The American Journal of Managed Care®. (CRANBURY, N.J.) — Drugs ...
As evidenced by the recent licensing deal between Pfizer and Protalix Biotherapeutics for the Gaucher disease treatment taliglucerase alfa, there is significant interest among big pharma companies in ...
Drugs used to treat rare conditions are earning pharmaceutical companies almost as much as those marketed to the general public, according to a researcher at West Virginia University. Sean Tu, a ...
A recent study of orphan drugs approved by the US Food and Drug Administration (FDA) finds that orphan products are more innovative than their non-orphan counterparts, representing roughly 40% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results